wer möchte auf Geld verdien verzichten

hoffffffffffffffnung.
Ach Börsenfan bin nicht  urlaub sondern hier in Deutschland wetter geht, ziehst dir einen dickern neopren anzug an dan geht die post ab  

Nach einem Anstieg um mehrere 100% ist durchaus mal Verkaufsdruck auf dem Wert.
Aber heute darf er nicht mehr so stark absacken. Sonst sieht es schlecht aus :-((

Mein Tipp, er zieht wieder an, bis 0,4 - 0,45 $...  

wird schon im bereich um 0,40-0,50 cent liegen  

ich sehe das als klaren kauf, der kurs ist super. Wo man bedenken muss das die aktie den tiefsten stand bei 0,10 hatte  

 

der Kurs enttäuscht mich, aber was nicht ist kann noch werden...  

echt scheiße damit habe ich auch nicht gerechnet, was nicht ist kann noch werden wie wahr wie wahr, scheiß Weltwirtschaft.
Konjungtur im Arsch könnte ruhig mal wieder anziehen.
Noch beschisssssener ist Caly.
G.Buch wollte doch 15 Mrd. Doller flüssig machen für Forschungszwecke im Gesundheitswesen, wird wohl dieses jahr nichts mehr...........

Alle reden keiner handelt  

 

die ganze Terror-Scheiße geht mir auch mächtig auf den Sack, kaum kommen irgendwelche Meldungen aus Nah-Ost über Terror-Planungen, geht´s runter an der Börse. Was ist denn mit Caly, läuft wohl doch nicht so wie es laufen sollte? Schau Dir mal BinTec an, die hat heute schon 200% gemacht, ich verstehe nur nicht warum. BinTec wird von Funkwerk übernommen, aber nur die Vertriebs-GmbH nicht der AG-Mantel - ergo die Aktie von BinTec
ist "eigentlich" nichts mehr Wert, aber sie steigt? Ich kapier gar nichts mehr...  

Man beachte den letzten Absatz in der
heutigen Bintec-Ad-Hoc:

"Gleichzeitig hat die Funkwerk AG (Köllada/Thüringen) die Geschäftsanteile der BinTec Access Networks GmbH erworben. Der Abschluss eines rechtsgültigen Kaufvertrages ist erfolgt.

Damit ist der operative Geschäftsbetrieb der BinTec Communications AG beendet. Für die Gläubiger wird voraussichtlich eine überdurchschnittliche Insolvenzquote zur Verteilung gelangen."

Nun hoffen die Aktionäre auf eine entsprechende Ablöse.
Ob das berechtigt ist?



 

;-))  

Profit Taking in Viragen  

Boston, May 21, 2003 (MidnightTrader via COMTEX) -- Seeing early profit-taking
in Viragen (VRA) this morning as the stock dips 4.6% on 248,650 Island shares.

VRA soared 258% in Tuesday's regular session after the company announced it
filed a patent application covering the use of natural human leukocyte-derived
alpha interferon for the treatment and prevention of severe acute respiratory
syndrome (SARS).

Stock is seeing volatile swings in the red, opening the door for quick-fingered
shorts.

Price: 0.41, Change: -0.02, Percent Change: -4.6

URL:              http://www.midnighttrader.com

So dann müssten wir ja wohl die "Shorties" von gestern aus dem Markt haben. Denke nicht dass sie den Wert noch weiter runter drücken!




 

nichts besonderes. Du mußt mal überlegen, dass einige (glückliche) Trader in den ersten Handelminuten fast von Anfang an dabei waren u. natürlich abstoßen.

SARS wird uns noch die nächsten Jahre beschäfigten. VRA hat noch mega-riese-Potential.

Das hier ist kein gepushe, da amerkanische Titel mit hohem Handelsvolumen niemals von Deutschland aus gepusht werden können.

Ich bin absolut 100%tig überzeugt, dass wir in den nächsten Wochen dicke Gewinne sehen werden.  

egal jetzt erst recht volles program  

bekommen.

Lets see! The party can beginn? Hat jmd Zugang zu vorbörslichen Handesspannen???  

Es wird spannend.
Vorbörsliche Quotes gibt es bei freerealtime.com (man muss sich allerdings kurz registrieren.)

Tamer, Börsenfan, Nukem !!! ...stellt schon mal den Sekt kalt! ;-))  

 

Was ist mit Dir passiert ?!?

@TB75F

Mit Sekt kalt stellen warte ich mal lieber, erstmal sehen wie sich der Kurs nach der Börseneröffnung in den USA entwickelt, aber 0,43 im Ask ist schonmal nicht schlecht....

Börsenfangrüße...  

Börsenfan siehste endlich wider sonnenschein  

 

   

as of May 22, 2003  

--------------------------------------------------

Symbol
Share Vol Price Chg  
 IVOC  95,951,300     0%    
 AMFR  88,080,000     -5%    
 MPTTE  60,214,700     50%    
 ZKEM  49,000,800     0%    
 IBZT  39,274,700     61.3%    
 USWH  31,382,700     -22.2%    
 AXGI  29,579,900     0%    
 USXP  29,015,200     13.6%    
 CALY  25,041,000     4%    
 CYIIE  22,048,100     50%    
         
     
     
     No Headlines Available

 Receive free OTCBB news updates




 


 Copyright © 2001. The Nasdaq Stock Market, Inc. Please read our Disclaimer and Privacy Statement.
 
 

PLANTATION, Fla., May 22 /PRNewswire-FirstCall/ -- Viragen, Inc. and Viragen International, Inc. (BULLETIN BOARD: VGNI) today announced that the Companies have entered into an exclusive distribution agreement with CJ Pharma, U.S. Pharmaceutical Division of CJ Corporation, and the CJ Hong Kong Ltd. subsidiary, as exclusive distributors of natural interferon in Hong Kong. Viragen''s human leukocyte-derived alpha interferon is currently approved in Hong Kong as a second-line therapy for the treatment of patients with Hairy Cell Leukemia (HCL) or Chronic Myelogenous Leukemia (CML) who did not respond to recombinant (synthetic) interferon regimens.

CJ Corporation (formerly Cheil Jedang) was established as the first manufacturing operation unit of the Samsung Group in 1953. Now a split-off of Samsung Group, the CJ Group recorded over $6 billion in revenues last year, conducting business with over 60 different countries through its thirty-two offices around the world.

"We are very pleased to build upon our relationship with a proven leader such as CJ Pharma," stated Viragen''s Executive Vice President, Mel Rothberg. "We have been working very closely with CJ to commercialize our natural interferon in previously assigned territories in Latin America. Now we are expanding our work together to include the introduction of the drug into the Hong Kong market."

CJ Pharma exclusively represents Viragen''s products in the following territories: Brazil, Chile, Uruguay, Peru, Costa Rica, Honduras, Nicaragua, Guatemala, Panama and Hong Kong. CJ Pharma is responsible for all costs associated with the regulatory approval process, including clinical trials if required, in each of the respective countries.

CJ Hong Kong''s General Manager, Mr. Jong Hwan Park, stated, "We are excited to attain the rights to distribute such a potent anti-viral product with Viragen''s multi-subtype human interferon. Our immediate priority is to expand the indications for which the product is currently approved to include a broad range of viral and malignant diseases and we are proceeding with the regulatory registration process."

Dr. Andrew Gorman, Vice President, CJ Pharma (Princeton, NJ), stated, "We believe that natural interferon represents a very attractive international market opportunity for us and our commitment to Viragen now extends from South America to Asia. Our foremost priority is to offer products that promote better health for everyone and this immune-enhancing drug offers that kind of promise in treating a variety of diseases."

Backgrounder:

The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond to standard therapy. In some instances, recombinant interferon is rejected by the patient''s immune system, usually caused by the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side-effects sometimes associated with recombinant therapy. High doses of recombinant interferon may cause serious, even life- threatening side effects.

The Natural Choice

Viragen believes that in many cases, especially when higher dosages are required, its natural interferon appears to offer substantial advantages to recombinant interferon regimens:

* Natural interferon is very similar to interferon secreted by the human immune system during a normal virus infection, significantly lowering the risk of the drug being rejected.

* Natural interferon contains the multiple subtype composition that is characteristic of interferon produced by the human body. It is believed that this may result in a broader spectrum of anti-viral activity with each subtype perhaps showing a specific biological activity.

* Natural interferon does not appear to cause the formation of neutralizing antibodies.

* Natural interferon is significantly less immunogenic than recombinant interferon. It should be far better tolerated by patients with fewer side effects and thus allow for higher doses to be administered to maximize the benefits of the therapy.

About CJ Corporation:

CJ Corporation (formerly Cheil Jedang) was established as the first manufacturing operation unit of the Samsung Group in 1953. The CJ Group recorded over $6 billion in revenues last year, conducting business with over 60 different countries through its thirty-two offices around the world. CJ Pharma is the pharmaceutical division in the U.S. and is the exclusive distributor of Viragen''s natural interferon in South America and Hong Kong.

About Viragen, Inc.

Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include human natural alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen''s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen''s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen''s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America''s Blood Centers and the German Red Cross.

For more information, please visit our Web site at: www.Viragen.com Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com CJ Pharma Contact: Jong H. Kim, Director, Global Commercial Phone: (609) 897-0780; Fax: (609) 897-0725 E-mail: jhkok@cj.net

The foregoing press release contains forward-looking statements that can be identified by such terminology such as "expects", "potential", "suggests", "may", "will", or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management''s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company''s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b AP Archive: http://photoarchive.ap.org/ PRN Photo Desk, 888-776-6555 or 212-782-2840 Viragen, Inc.

© PR Newswire
 

es tut sich was, tolle Nachrichten  

das hört sich wirklich nicht schlecht an...  

in hoffnung voller erwartungen ist es bald so weit, man oh man dieses hin und her macht mein Herz bald nicht mehr mit.
Doch sieht man eine festigung im Wert.
Gut das ich gestern nochmals 30.000 tsd gekauft habe zu 0,24, hat sich bislang völlig gelohnt der nachkauf.
Wie siehts bei dir aus ??????????????